Myasthenia gravis complement activity is independent of autoantibody titer and disease severity.
Acetylcholine receptor (AChR) autoantibodies, found in patients with autoimmune myasthenia gravis (MG), can directly contribute to disease pathology through activation of the classical complement pathway. Activation of the complement pathway in autoimmune diseases can lead to a secondary complement...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0264489 |
| _version_ | 1797862058613538816 |
|---|---|
| author | Miriam L Fichtner Michelle D Hoarty Douangsone D Vadysirisack Bailey Munro-Sheldon Richard J Nowak Kevin C O'Connor |
| author_facet | Miriam L Fichtner Michelle D Hoarty Douangsone D Vadysirisack Bailey Munro-Sheldon Richard J Nowak Kevin C O'Connor |
| author_sort | Miriam L Fichtner |
| collection | DOAJ |
| description | Acetylcholine receptor (AChR) autoantibodies, found in patients with autoimmune myasthenia gravis (MG), can directly contribute to disease pathology through activation of the classical complement pathway. Activation of the complement pathway in autoimmune diseases can lead to a secondary complement deficiency resulting in reduced complement activity, due to consumption, during episodes of disease activity. It is not clear whether complement activity in MG patients associates with measurements of disease activity or the titer of circulating pathogenic AChR autoantibodies. To explore such associations, as a means to identify a candidate biomarker, we measured complement activity in AChR MG samples (N = 51) using a CH50 hemolysis assay, then tested associations between these values and both clinical status and AChR autoantibody titer. The majority of the study subjects (88.2%) had complement activity within the range defined by healthy controls, while six patients (11.8%) showed reduced activity. No significant association between complement activity and disease status or AChR autoantibody titer was observed. |
| first_indexed | 2024-04-09T22:14:22Z |
| format | Article |
| id | doaj.art-b75d42d92931411eb99c395140042294 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-09T22:14:22Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-b75d42d92931411eb99c3951400422942023-03-23T05:32:10ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01173e026448910.1371/journal.pone.0264489Myasthenia gravis complement activity is independent of autoantibody titer and disease severity.Miriam L FichtnerMichelle D HoartyDouangsone D VadysirisackBailey Munro-SheldonRichard J NowakKevin C O'ConnorAcetylcholine receptor (AChR) autoantibodies, found in patients with autoimmune myasthenia gravis (MG), can directly contribute to disease pathology through activation of the classical complement pathway. Activation of the complement pathway in autoimmune diseases can lead to a secondary complement deficiency resulting in reduced complement activity, due to consumption, during episodes of disease activity. It is not clear whether complement activity in MG patients associates with measurements of disease activity or the titer of circulating pathogenic AChR autoantibodies. To explore such associations, as a means to identify a candidate biomarker, we measured complement activity in AChR MG samples (N = 51) using a CH50 hemolysis assay, then tested associations between these values and both clinical status and AChR autoantibody titer. The majority of the study subjects (88.2%) had complement activity within the range defined by healthy controls, while six patients (11.8%) showed reduced activity. No significant association between complement activity and disease status or AChR autoantibody titer was observed.https://doi.org/10.1371/journal.pone.0264489 |
| spellingShingle | Miriam L Fichtner Michelle D Hoarty Douangsone D Vadysirisack Bailey Munro-Sheldon Richard J Nowak Kevin C O'Connor Myasthenia gravis complement activity is independent of autoantibody titer and disease severity. PLoS ONE |
| title | Myasthenia gravis complement activity is independent of autoantibody titer and disease severity. |
| title_full | Myasthenia gravis complement activity is independent of autoantibody titer and disease severity. |
| title_fullStr | Myasthenia gravis complement activity is independent of autoantibody titer and disease severity. |
| title_full_unstemmed | Myasthenia gravis complement activity is independent of autoantibody titer and disease severity. |
| title_short | Myasthenia gravis complement activity is independent of autoantibody titer and disease severity. |
| title_sort | myasthenia gravis complement activity is independent of autoantibody titer and disease severity |
| url | https://doi.org/10.1371/journal.pone.0264489 |
| work_keys_str_mv | AT miriamlfichtner myastheniagraviscomplementactivityisindependentofautoantibodytiteranddiseaseseverity AT michelledhoarty myastheniagraviscomplementactivityisindependentofautoantibodytiteranddiseaseseverity AT douangsonedvadysirisack myastheniagraviscomplementactivityisindependentofautoantibodytiteranddiseaseseverity AT baileymunrosheldon myastheniagraviscomplementactivityisindependentofautoantibodytiteranddiseaseseverity AT richardjnowak myastheniagraviscomplementactivityisindependentofautoantibodytiteranddiseaseseverity AT kevincoconnor myastheniagraviscomplementactivityisindependentofautoantibodytiteranddiseaseseverity |